Comparison of antiproliferative effects of metformine and progesterone on estrogen-induced endometrial hyperplasia in rats

References

• Dizon DS. Treatment options for advanced endometrial carcinoma. Gynecol Oncol 2010;117:373–81
   PubMed Web of Science ®Google Scholar
• Ehrlich CE, Young PC, Stehman FB, et al. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 1988;158:796–807
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999;17:1736–44
   PubMed Web of Science ®Google Scholar
• Lange CA, Richer JK, Shen T, Horwitz KB. Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem 1998;273:31308–16
   PubMed Web of Science ®Google Scholar
• Daniel AR, Knutson TP, Lange CA. Signaling inputs to progesterone receptor gene regulation and promoter selectivity. Mol Cell Endocrinol 2009;308:47–52
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625–38
   PubMed Web of Science ®Google Scholar
• Giudice LC. Endometrium in PCOS: implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab 2006;20:235–44
   PubMed Web of Science ®Google Scholar
• Ciotta L, De Leo V, Farina M, et al. Endocrine and metabolic effects of insulin sensitizers in the treatment of patients with polycystic ovary syndrome and hyperinsulinaemia. Gynecol Obstet Invest 2001;51:44–50
   PubMedGoogle Scholar
• Garmes HM, Tambascia MA, Zantut-Wittmann DE. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005;21:317–23
   PubMed Web of Science ®Google Scholar
• Lemay A, Dodin S, Turcot L, et al. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance. Hum Reprod 2006;21:121–8
   PubMed Web of Science ®Google Scholar
• Bjørge T, Lukanova A, Jonsson H, et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev 2010;19:1737–45
   PubMed Web of Science ®Google Scholar
• Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999;24:68–72
   PubMed Web of Science ®Google Scholar
• Tan BK, Adya R, Chen J, et al. Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab 2011;96:808–16
   PubMed Web of Science ®Google Scholar
• Kumasaka T, Itoh E, Watanabe H, et al. Effects of various forms of progestin on the endometrium of the estrogen-primed, ovariectomized rat. Endocr J 1994;41:161–9
   PubMedGoogle Scholar
• Erdemoglu E, Güney M, Giray SG, et al. Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol 2009;145:195–9
   PubMed Web of Science ®Google Scholar
• Oner G, Ozcelik B, Ozgun MT, Ozturk F. The effects of metformin and letrozole on endometrium and ovary in a rat model. Gynecol Endocrinol 2011;27:1084–6
   PubMed Web of Science ®Google Scholar
• Mutter GL, Zaino RJ, Baak JP, et al. Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol 2007;26:103–14
   PubMedGoogle Scholar
• Gambrell RD Jr, Bagnell CA, Greenblatt RB. Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: review. Am J Obstet Gynecol 1983;146:696–707
   PubMedGoogle Scholar
• Alvizouri M. Effect of progesterone on experimental endometrial hyperplasia. Am J Obstet Gynecol 1961;82:1224–7
   PubMedGoogle Scholar
• Gelfand M, Ferenczy A. Prospective 1-year study of estrogen and progestin in postmenopausal women: effects on the endometrium. Obstet Gynecol 1989;74:398–402
   PubMed Web of Science ®Google Scholar
• Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000;73:1149–54
   PubMed Web of Science ®Google Scholar
• Yarali H, Yildiz BO, Demirol A, et al. Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum Reprod 2002;17:289–94
   PubMed Web of Science ®Google Scholar
• Kjøtrød SB, Carlsen SM, Rasmussen PE, et al. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Hum Reprod 2011;26:2045–53
   PubMed Web of Science ®Google Scholar
• Shen ZQ, Zhu HT, Lin JF. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol 2008;112:465–7
   PubMed Web of Science ®Google Scholar
• Roy RN, Gerulath AH, Cecutti A, Bhavnani BR. Discordant expression of insulin-like growth factors and their receptor messenger ribonucleic acids in endometrial carcinomas relative to normal endometrium. Mol Cell Endocrinol 1999;153:19–27
   PubMedGoogle Scholar
• Navarro M, Baserga R. Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor. Endocrinology 2001;142:1073–81
   PubMed Web of Science ®Google Scholar
• Algire C, Zakikhani M, Blouin MJ, et al. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 2008;15:833–9
   PubMedGoogle Scholar
• Capp E, Jauckus J, von Eye Corleta H, et al. Does metformin influence the insulin-, IGF I- and IGF II-receptor gene expression and Akt phosphorylation in human decidualized endometrial stromal cells? Eur J Obstet Gynecol Reprod Biol 2011;158:248–53
   PubMedGoogle Scholar
• Xie Y, Wang YL, Yu L, et al. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol 2011;126:113–20
   PubMed Web of Science ®Google Scholar
• Treeck O, Wackwitz B, Haus U, Ortmann O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 2006;102:292–9
   PubMed Web of Science ®Google Scholar
• Oner G, Ozcelik B, Ozgun MT, et al. The effects of metformin and letrozole on endometriosis and comparison of the two treatment agents in a rat model. Hum Reprod 2010;25:932–7
   PubMed Web of Science ®Google Scholar
• Yilmaz B, Sucak A, Kilic S, et al. Metformin regresses endometriotic implants in rats by improving implant levels of superoxide dismutase, vascular endothelial growth factor, tissue inhibitor of metalloproteinase-2, and matrix metalloproteinase-9. Am J Obstet Gynecol 2010;202:368.e1–8
   Google Scholar
• Meresman GF, Bilotas M, Abello V, et al. Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis. Fertil Steril 2005;84:459–63
   PubMed Web of Science ®Google Scholar
• Takemura Y, Osuga Y, Yoshino O, et al. Metformin suppresses interleukin (IL) 1beta-induced IL-8 production, aromatase activation, and proliferation of endometriotic stromal cells. J Clin Endocrinol Metab 2007;92:3213–8
   PubMed Web of Science ®Google Scholar
• Samarajeewa NU, Ham S, Yang F, et al. Promoter-specific effects of metformin on aromatase transcript expression. Steroids 2011;76:768–71
   PubMedGoogle Scholar